Additional Proxy Soliciting Materials (definitive) (defa14a)
April 28 2020 - 4:33PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934
Filed by the
Registrant ☒ Filed by a Party other than the
Registrant ☐
Check the appropriate box:
|
|
|
☐
|
|
Preliminary Proxy Statement
|
|
|
☐
|
|
Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2))
|
|
|
☐
|
|
Definitive Proxy Statement
|
|
|
☒
|
|
Definitive Additional Materials
|
|
|
☐
|
|
Soliciting Material Under Rule 14a-12
|
Adverum
Biotechnologies, Inc.
(Name of Registrant as Specified in its Charter)
Payment of Filing Fee (Check the appropriate box):
|
|
|
|
|
|
|
☒
|
|
No fee required
|
|
|
☐
|
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
|
|
|
|
(1)
|
|
Title of each class of securities to which transaction applies:
|
|
|
(2)
|
|
Aggregate number of securities to which transaction applies:
|
|
|
(3)
|
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing
fee is calculated and state how it was determined):
|
|
|
(4)
|
|
Proposed maximum aggregate value of transaction:
|
|
|
(5)
|
|
Total fee paid:
|
☐
|
|
Fee paid previously with preliminary
materials.
|
|
|
☐
|
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement
number, or the form or schedule and the date of its filing.
|
|
|
|
|
|
(1)
|
|
Amount Previously Paid:
|
|
|
(2)
|
|
Form, Schedule or Registration Statement No.:
|
|
|
(3)
|
|
Filing Party:
|
|
|
(4)
|
|
Date Filed:
|
*** Exercise Your Right to Vote ***
Important
Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to Be Held on June 23, 2020.
ADVERUM BIOTECHNOLOGIES, INC.
Meeting Information
Meeting Type: Annual Meeting
For holders as of: April 27, 2020
Date: June 23, 2020 Time: 8:00 a.m. PDT Location: Meeting
live via the Internet-please visit www.virtualshareholdermeeting.com/ADVM2020.
The company will be hosting the meeting live via the Internet this year. To attend
the meeting via the Internet please visit www.virtualshareholdermeeting.com/ADVM2020 and be sure to have the information that is printed in the box marked by the arrow gXXXX XXXX XXXX XXXX (located
on the following page).
You are receiving this communication because you hold shares in the company named above.
This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you
on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).
We encourage you to access and
review all of the important information contained in the proxy materials before voting.
See the reverse side of this notice to obtain proxy materials and voting
instructions.
ADVERUM BIOTECHNOLOGIES, INC. 800 SAGINAW DRIVE
REDWOOD CITY,
CA 94063
D16270-P40901
Before You Vote
How to Access the Proxy Materials
Proxy Materials Available to VIEW or RECEIVE:
NOTICE AND PROXY STATEMENT FORM 10-K
How to View Online:
Have the information that is printed in the box marked by the arrow gXXXX XXXX XXXX XXXX (located on the following page) and
visit: www.proxyvote.com.
How to Request and Receive a PAPER or E-MAIL Copy:
If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the
following methods to make your request: 1) BY INTERNET: www.proxyvote.com 2) BY TELEPHONE: 1-800-579-1639 3) BY E-MAIL*: sendmaterial@proxyvote.com
* If requesting
materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow gXXXX XXXX XXXX XXXX (located on the following page) in the subject line.
Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed
above on or before June 9, 2020 to facilitate timely delivery.
How To Vote
Please Choose One of the Following Voting Methods
Vote By Internet:
Before The Meeting:
Go to www.proxyvote.com. Have the information that is
printed in the box marked by the arrow gXXXX XXXX XXXX XXXX (located on the following page) available and follow the instructions.
During The Meeting:
Go to www.virtualshareholdermeeting.com/ADVM2020. Have the information
that is printed in the box marked by the arrow gXXXX XXXX XXXX XXXX (located on the following page) available and follow the instructions.
Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.
D16271-P40901
Voting Items
The Board of Directors recommends you
vote FOR the following:
1. Election of Directors
Nominees
01) Mehdi Gasmi, Ph.D. 02) Mark Lupher, Ph.D. 03) Scott M. Whitcup, M.D.
The
Board of Directors recommends you vote FOR the following proposals:
2. To ratify the selection, by the Audit Committee of our board of directors, of
Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2020.
3. To approve, on an advisory basis, the
compensation of our named executive officers as disclosed in the proxy statement.
The Board of Directors recommends you vote ONE YEAR for the following
proposal:
4. To approve, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of our named executive officers.
NOTE: In their discretion, the proxyholders are authorized to vote upon such other business as may properly come before the meeting and any adjournment or
postponement thereof.
D16272-P40901
D16273-P40901
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Sep 2023 to Sep 2024